Revolutionary $1K Blood Test Disrupts Cancer Treatment
Grail's Galleri test, a multicancer early detection test that screens for over 50 types of cancer, is gaining popularity among wealthy patients despite concerns from some doctors. The $949 test, not covered by most insurance plans, has shown potential in early detection but has also raised red flags due to a significant number of false positives and false negatives. The test is not yet FDA-approved, and the American Academy of Family Physicians does not recommend mass screenings. Additionally, a recent software error resulted in false negative reports being sent to customers. Grail is working on independent studies to track its accuracy and seeking wider insurance coverage.
